Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TILT Biotherapeutics to Collaborate with Merck KGaA and Pfizer | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

TILT Biotherapeutics to Collaborate with Merck KGaA and Pfizer

To investigate the combination of oncolytic virus, TILT-123, and anti-PDL1 antibody, avelumab

By: Cassandra Gervolino

TILT Biotherapeutics Ltd. has entered into an agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.
 
“We are pleased to initiate a collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to translate our findings into patients. Preclinical results with TILT-technology and anti-PD(L)1 agents suggest immune activation and efficacy in certain animal models,” said Akseli Hemminki, chief executive officer and founder, TILT Biotherapeutics.
 
Avelumab is currently under clinical investigation in combination with TILT-123 for treatment of solid tumors and has not been demonstrated to be safe and effective for this use. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics